ATE476497T1 - Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie - Google Patents
Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapieInfo
- Publication number
- ATE476497T1 ATE476497T1 AT05763875T AT05763875T ATE476497T1 AT E476497 T1 ATE476497 T1 AT E476497T1 AT 05763875 T AT05763875 T AT 05763875T AT 05763875 T AT05763875 T AT 05763875T AT E476497 T1 ATE476497 T1 AT E476497T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- antigen
- immunotherapy
- preparation
- human
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 8
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 210000005259 peripheral blood Anatomy 0.000 abstract 1
- 239000011886 peripheral blood Substances 0.000 abstract 1
- 230000008569 process Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/46482—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04405516 | 2004-08-19 | ||
| EP05007214 | 2005-04-01 | ||
| PCT/CH2005/000469 WO2006017954A1 (en) | 2004-08-19 | 2005-08-11 | PREPARATION OF ANTIGEN-PRESENTING HUMAN Ϝδ T CELLS AND USE IN IMMUNOTHERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE476497T1 true ATE476497T1 (de) | 2010-08-15 |
Family
ID=34980276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05763875T ATE476497T1 (de) | 2004-08-19 | 2005-08-11 | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8153426B2 (de) |
| EP (1) | EP1778836B1 (de) |
| JP (1) | JP5016489B2 (de) |
| AT (1) | ATE476497T1 (de) |
| AU (1) | AU2005274649B2 (de) |
| CA (1) | CA2576571C (de) |
| DE (1) | DE602005022728D1 (de) |
| DK (1) | DK1778836T3 (de) |
| HK (1) | HK1103104A1 (de) |
| NZ (1) | NZ553055A (de) |
| WO (1) | WO2006017954A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1778836T3 (da) | 2004-08-19 | 2010-11-22 | Univ Cardiff | Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi |
| US8338173B2 (en) | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
| JPWO2008111430A1 (ja) * | 2007-03-09 | 2010-06-24 | タカラバイオ株式会社 | γδＴ細胞集団の製造方法 |
| US8012466B2 (en) | 2008-01-31 | 2011-09-06 | University Of Iowa Research Foundation | Immunogenic compositions for activating γδ T cells |
| CN102277330B (zh) * | 2011-06-16 | 2013-08-28 | 清华大学深圳研究生院 | 人CD3+CD8+γδT淋巴细胞及其制备方法与应用 |
| WO2014170867A1 (en) | 2013-04-18 | 2014-10-23 | Institut National De La Sante Et De La Recherche Medicale | Composition with reduced immunogenicity |
| JP2017524031A (ja) * | 2014-07-09 | 2017-08-24 | ティーシー バイオファーム リミテッド | ガンマデルタｔ細胞およびその使用 |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| KR20230132604A (ko) | 2015-01-27 | 2023-09-15 | 라바 테라퓨틱스 엔.브이. | Cd1d를 표적화하는 단일 도메인 항체 |
| US11613759B2 (en) | 2015-09-04 | 2023-03-28 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用ＣＤ１ｄ免疫グロブリン |
| EP4045635A4 (de) * | 2019-10-17 | 2023-10-25 | The University of Hong Kong | Verfahren zur herstellung von aus v-t-zellen abgeleiteten exosomen zur behandlung von mit epstein-barr-virus assoziierten karzinomen |
| AU2021338354A1 (en) * | 2020-09-02 | 2023-04-20 | Serhat GUMRUKCU | Expanded memory subsets of gamma delta T cells for immunotherapy |
| CN112410297B (zh) * | 2020-11-30 | 2022-05-24 | 北京荟科柘生物科技有限公司 | 一种γδT样αβT细胞及其制备方法和应用 |
| EP4183871A1 (de) | 2021-11-23 | 2023-05-24 | Université d'Aix-Marseille | Verfahren zur herstellung einer zusammensetzung mit einer kombinierten zellpopulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5788963A (en) * | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US5747332A (en) | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
| EP2058389B1 (de) | 1997-10-27 | 2016-05-18 | Rockefeller University | Definiertes Reifungsmedium für dendritische Zellen enthaltend TNF-alpha, IL-1beta, IL-6 |
| ES2319942T3 (es) * | 1998-11-04 | 2009-05-14 | Therapure Biopharma Inc. | Procedimientos para la produccion de celulas t tcr gamma delta. |
| FR2836483B1 (fr) | 2002-02-22 | 2006-09-15 | Innate Pharma | Procedes de production de lymphocytes gamma delta t |
| DE60233576D1 (de) | 2002-12-02 | 2009-10-15 | Innate Pharma | Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen |
| WO2004084940A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| DK1778836T3 (da) | 2004-08-19 | 2010-11-22 | Univ Cardiff | Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi |
| US20090208517A1 (en) | 2004-08-19 | 2009-08-20 | Bernhard Moser | Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy |
-
2005
- 2005-08-11 DK DK05763875.1T patent/DK1778836T3/da active
- 2005-08-11 AU AU2005274649A patent/AU2005274649B2/en not_active Ceased
- 2005-08-11 JP JP2007526161A patent/JP5016489B2/ja not_active Expired - Fee Related
- 2005-08-11 WO PCT/CH2005/000469 patent/WO2006017954A1/en active Application Filing
- 2005-08-11 CA CA2576571A patent/CA2576571C/en not_active Expired - Fee Related
- 2005-08-11 NZ NZ553055A patent/NZ553055A/en not_active IP Right Cessation
- 2005-08-11 US US11/573,912 patent/US8153426B2/en not_active Expired - Fee Related
- 2005-08-11 DE DE602005022728T patent/DE602005022728D1/de active Active
- 2005-08-11 AT AT05763875T patent/ATE476497T1/de not_active IP Right Cessation
- 2005-08-11 EP EP05763875A patent/EP1778836B1/de not_active Not-in-force
-
2007
- 2007-09-27 HK HK07110531.8A patent/HK1103104A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2576571C (en) | 2013-07-02 |
| NZ553055A (en) | 2008-12-24 |
| US8153426B2 (en) | 2012-04-10 |
| DE602005022728D1 (de) | 2010-09-16 |
| AU2005274649A1 (en) | 2006-02-23 |
| US20080075732A1 (en) | 2008-03-27 |
| DK1778836T3 (da) | 2010-11-22 |
| HK1103104A1 (en) | 2007-12-14 |
| JP2008509683A (ja) | 2008-04-03 |
| CA2576571A1 (en) | 2007-02-08 |
| JP5016489B2 (ja) | 2012-09-05 |
| EP1778836B1 (de) | 2010-08-04 |
| AU2005274649B2 (en) | 2010-09-09 |
| EP1778836A1 (de) | 2007-05-02 |
| WO2006017954A1 (en) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE476497T1 (de) | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie | |
| AU2006288348B2 (en) | Method for activation treatment of antigen-presenting cell | |
| US9211321B2 (en) | Method for proliferation of antigen-specific T cells | |
| KR102501827B1 (ko) | 바이러스-특이적인 t-세포의 활성화 및 확장을 위한 플랫폼 | |
| CN103502439B (zh) | 用于抗原特异性t细胞增殖的方法 | |
| DK2311470T3 (en) | A method for simultaneous induction of CTLs and gamma delta T cells | |
| JP2014514927A5 (de) | ||
| CN103533955A (zh) | 用于激发t细胞的方法 | |
| TW201741330A (zh) | Ｔ細胞增生技術 | |
| Harfuddin et al. | CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses | |
| JP2018511320A (ja) | 治療およびエピトープマッピング用Ｔ細胞の感作および増殖のためのｉｎ ｖｉｔｒｏ人工リンパ節法 | |
| de Lastic et al. | Effect of dendritic cell state and antigen-presentation conditions on resulting T-cell phenotypes and Th cytokine profiles | |
| CN101321861B (zh) | 采用降低的温度产生树突细胞的方法 | |
| Kuriyama et al. | Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination | |
| CN105219723A (zh) | 一种用于激活胃癌特异性免疫反应的试剂盒 | |
| US20170021002A1 (en) | Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors | |
| Wang et al. | The ex vivo microenvironments in MLTC of poorly immunogenic tumor cells facilitate polarization of CD4+ CD25+ regulatory T cells | |
| CN105219716A (zh) | 一种用于激活头颈部癌特异性免疫反应的试剂盒 | |
| CN105219725A (zh) | 一种用于激活肉瘤特异性免疫反应的试剂盒 | |
| CN105219724A (zh) | 一种用于激活黑色素瘤特异性免疫反应的试剂盒 | |
| WO2013063713A1 (zh) | 诱发产生综合免疫细胞的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |